Durham scientists and collaborators around the country are in a high-speed hunt for pain relief that does not come with an opioid habit attached. They are testing treatments that calm pain-signaling cells and even try to repair the tiny power plants inside damaged nerves, with the goal of tackling pain at its biological roots instead of just dulling the symptoms. For Raleigh resident Malia Baird, who says she lives with nonstop nerve pain, those experiments are more than abstract science - they feel like a rare and concrete source of hope.
As reported by News4JAX, Baird described the sensation as "terrible burning pain like standing in a fire" and said, "I have pain 24 hours every day and will for the rest of my life." The June 25 piece by Melanie Lawson used Baird's story to underscore why researchers are pushing so hard for options that control pain without feeding addiction.
Mitochondria repair targets nerves
Duke University researchers reported that satellite glial cells can deliver healthy mitochondria to sensory neurons and that restoring those energy supplies reduced pain behaviors in mice and in human tissue. The work suggests a potential path to treatments for diabetic neuropathy and chemotherapy-induced nerve damage.
As detailed by Duke University School of Medicine, senior author Ru-Rong Ji said, "By giving damaged nerves fresh mitochondria - or helping them make more of their own - we can reduce inflammation and support healing." The team emphasized that they still need to refine imaging tools and delivery methods before they can even think about testing this approach in people.
Next-gen drugs that skip the high
A separate study published in Cell described SBI-810, a compound that activates a particular pain-relief pathway on sensory neurons and in the spinal cord. In mice, the molecule produced strong analgesia without the usual opioid side effects. In animal tests it worked on its own and also boosted the effects of opioids at lower doses, hinting at a possible role as a safer add-on to existing pain regimens.
Investigators point out that results in animals do not guarantee that the same benefits will show up in humans, but the work gives chemists a clearer molecular target as they chase non-addictive pain medicines.
Revisiting old chemistry for safer opioids
Scientists at the National Institutes of Health went back to a class of nitazene compounds and reported a formulation whose metabolite, DFNZ, relieved pain in rats while showing fewer signs of respiratory depression, tolerance and dependence than traditional opioids. According to the NIH team, DFNZ produced sustained analgesia without the rapid dopamine bursts that drive cue-associated craving in addiction studies.
They stressed that more preclinical testing is needed before any human trials, but the findings point to one possible route toward safer opioid pharmacology that could sit alongside fully non-opioid strategies.
Different molecular paths, same goal
Other teams are trying to pull different biological levers. Researchers at Rensselaer Polytechnic Institute described a reversible GlyT2-targeting compound, RPI-GLYT2-82, that eased neuropathic pain in preclinical models without neuromotor side effects or signs of addiction.
Taken together, these structural and mechanistic advances - from transporter modulation to receptor biasing and organelle repair - give drug developers several paths to try to maximize pain relief while trimming the risk of dependence.
Scale of the problem
The stakes are big. A Centers for Disease Control and Prevention analysis of national survey data estimated that about one in five U.S. adults, roughly 51.6 million people in 2021, lived with chronic pain, which drives heavy demand for treatments. At the same time, systematic reviews have found that roughly 21 to 29 percent of patients prescribed opioids for chronic pain may misuse them, with a smaller share developing opioid use disorder, which helps explain why safer alternatives are a public-health priority (CDC; Vowles et al., Pain).
What’s next for patients
Researchers interviewed for the News4JAX story said that human clinical trials could follow if the preclinical data keep looking promising and if they can solve practical hurdles around safety, delivery and funding.
As reported by News4JAX, teams ultimately envision pain care that blends targeted medicines, mitochondrial repair strategies and non-drug approaches in an effort to reduce both suffering and the risk of creating new dependencies. For people like Baird, those layered strategies may one day offer relief that does not trade one crisis for another.
